新型放射性药物与泌尿生殖系统肿瘤诊疗一体化未来
本综述系统检索PubMed/MEDLINE与ClinicalTrials.gov,纳入46篇前瞻性原始研究并识别74项正在进行的临床试验,汇总27种新型放射性药物在泌尿生殖系统肿瘤(以前列腺癌为主)中的诊断、诊疗一体化或治疗应用,确认其安全性并在诊断准确性与疗效方面显示有前景的结果。
要点
- 系统综述纳入46篇前瞻性研究,识别74项正在进行的临床试验。
- 27种新型放射性药物中17种靶向前列腺特异性膜抗原(PSMA)。
- 22项正在进行的治疗试验中12项探索靶向α治疗。
核心结论
- 泌尿生殖系统肿瘤的放射性药物方法持续扩展,反映对改善肿瘤检测与治疗的强烈关注,可能影响未来疾病全程管理并有望改善患者照护与结局。
研究设计与样本
- 本综述遵循系统综述与Meta分析首选报告条目(PRISMA)指南,系统检索PubMed/MEDLINE与ClinicalTrials.gov的前瞻性原始研究。
- 系统综述共纳入46篇论文,并识别74项正在进行的临床试验。
主要发现
- 过去5年前瞻性研究的27种新型放射性药物中,21种用于诊断、1种用于诊疗一体化、5种用于治疗,主要针对前列腺癌。
- 27种放射性药物中大多数为靶向前列腺特异性膜抗原(PSMA)的制剂(17/27)。
- 其他靶点包括胃泌素释放肽受体、碳酸酐酶IX、Cu、六次跨膜上皮抗原1、肿瘤相关糖蛋白42和尿激酶型纤溶酶原激活物受体。
- 74项正在进行的临床试验中22项为治疗试验,其中12项探索靶向α治疗,5项评估放射性配体治疗与其他治疗的联合。
- 研究确认放射性药物(无论诊断或治疗目的)的安全性,并在泌尿生殖系统肿瘤中显示有前景的诊断准确性与治疗疗效结果。
关键数值与推荐
- 正在研究的其他靶点包括成纤维细胞活化蛋白抑制剂、PD-L1、CD8、nectin-4和HER2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This review aims to provide an overview of novel diagnostic and therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers within prospective phase 1-2 clinical trials, summarizing progresses and future directions. METHODS: A systematic search was conducted using the PubMed/MEDLINE and ClinicalTrials.gov databases for original prospective research studies following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. KEY FINDINGS AND LIMITATIONS: Forty-six papers were systematically reviewed; 74 ongoing clinical trials were identified. The results of 27 novel radiopharmaceuticals (ie, not approved by the Food and Drug Administration/European Medicines Agency and not listed in the Pharmacopeia) prospectively investigated in genitourinary cancers, mostly prostate, for diagnostic, theranostic, or therapeutic purposes (21, one, and five of the 27 radiopharmaceuticals, respectively) over the past 5 yr were presented. Most were prostate-specific membrane antigen-targeting agents (17/27); other targets included gastrin-releasing peptide receptor, carbonic anhydrase IX, Cu, six transmembrane epithelial antigen of the prostate 1, tumor-associated glycoprotein 42, and urokinase-type plasminogen activator receptor. Ongoing research confirms the same trend. Fibroblast activation protein inhibitor, PD-L1, CD8, nectin-4, and HER2 are other targets under investigation. Among the 22 ongoing therapeutic trials (out of the 74 ongoing clinical trials), targeted alpha therapy is being explored in 12, and five are evaluating combinations of radioligand therapy with other treatments. We confirmed the safety of radiopharmaceuticals (regardless of the diagnostic/therapeutic purpose) and showed promising results in terms of diagnostic accuracy and therapeutic efficacy in genitourinary cancers. CONCLUSIONS AND CLINICAL IMPLICATIONS: There continues to be expansion in radiopharmaceutical approaches to genitourinary cancers, reflecting a strong emphasis on improving tumor detection and treatment, which will likely impact future management across the disease spectrum, with the potential for improved patient care and outcomes.
引用
- Sollini M, Calais J, Chiti A, et al. Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers. Eur Urol. 2024. PMID: 39428326. doi:10.1016/j.eururo.2024.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。